Scarica l'app Stockscreener
1.535
0.65%
-0.005
Precedente Chiudi:
$1.54
Aprire:
$1.51
Volume 24 ore:
876.87K
Relative Volume:
0.21
Capitalizzazione di mercato:
$408.66M
Reddito:
$194.75M
Utile/perdita netta:
$-51.26M
Rapporto P/E:
-5.4821
EPS:
-0.28
Flusso di cassa netto:
$-23.38M
1 W Prestazione:
-8.38%
1M Prestazione:
-50.96%
6M Prestazione:
-45.55%
1 anno Prestazione:
-15.93%
Intervallo 1D:
$1.49
$1.55
Intervallo di 1 settimana:
$1.49
$1.835
Portata 52W:
$1.49
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Nome
Akebia Therapeutics Inc
Settore
Telefono
617-871-2098
Indirizzo
245 FIRST STREET, CAMBRIDGE, MA
Confronta AKBA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.54 | 408.66M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
118.11 | 51.07B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.30 | 44.42B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.905 | 42.75B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.16 | 27.86B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
472.33 | 20.44B | 3.08B | 1.24B | 1.07B | 25.61 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-04 | Ripresa | H.C. Wainwright | Buy |
| 2025-04-28 | Iniziato | Leerink Partners | Outperform |
| 2025-04-01 | Iniziato | Jefferies | Buy |
| 2023-11-29 | Ripresa | BTIG Research | Buy |
| 2023-08-28 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-31 | Downgrade | Needham | Buy → Hold |
| 2022-03-31 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Reiterato | Needham | Buy |
| 2019-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-11 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-02 | Iniziato | JP Morgan | Overweight |
| 2019-03-20 | Iniziato | Citigroup | Neutral |
| 2018-09-07 | Ripresa | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Reiterato | Needham | Buy |
| 2018-06-06 | Reiterato | H.C. Wainwright | Buy |
| 2017-12-19 | Iniziato | Piper Jaffray | Overweight |
| 2017-12-07 | Iniziato | BTIG Research | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | Needham | Buy |
| 2016-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2016-12-20 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-11-15 | Iniziato | Aegis Capital | Buy |
| 2016-09-29 | Iniziato | Brean Capital | Buy |
| 2016-03-16 | Reiterato | Needham | Buy |
| 2016-01-21 | Iniziato | Credit Suisse | Neutral |
Mostra tutto
Akebia Therapeutics Inc Borsa (AKBA) Ultime notizie
How forex fluctuations impact Akebia Therapeutics Inc. (AX9) stockWeekly Loss Report & Reliable Intraday Trade Plans - newser.com
How Akebia Therapeutics Inc. stock compares to market leadersPortfolio Risk Summary & Growth Focused Entry Point Reports - newser.com
What analyst consensus implies for Akebia Therapeutics Inc. (AX9) stockCEO Change & AI Forecasted Entry/Exit Points - newser.com
Is Akebia Therapeutics Inc. stock cheap at current valuationBond Market & Weekly High Potential Stock Alerts - newser.com
Live market analysis of Akebia Therapeutics Inc.Portfolio Gains Report & Real-Time Sentiment Analysis - newser.com
How Akebia Therapeutics Inc. (AX9) stock gains from tech spendingTrade Entry Report & Free Verified High Yield Trade Plans - newser.com
How Akebia Therapeutics Inc. (AX9) stock behaves in tightening cyclesMarket Volume Summary & Expert Curated Trade Setups - newser.com
Signal strength of Akebia Therapeutics Inc. stock in tech scannersJuly 2025 Opening Moves & Low Risk Entry Point Guides - newser.com
Is Akebia Therapeutics Inc. stock a safe investment in uncertain markets2025 AllTime Highs & Low Drawdown Investment Strategies - newser.com
How strong dollar benefits Akebia Therapeutics Inc. (AX9) stock - newser.com
Tools to assess Akebia Therapeutics Inc.’s risk profileJuly 2025 Weekly Recap & Stock Portfolio Risk Control - newser.com
Brokerages Set Akebia Therapeutics, Inc. (NASDAQ:AKBA) Price Target at $6.00 - Defense World
This trade activity should not be overlooked: Akebia Therapeutics Inc (AKBA) - Setenews
Levi & Korsinsky Announces an Investigation on Behalf of Akebia Therapeutics, Inc. (AKBA) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
AKBA: Vafseo's expanding access and strong clinical data position it for standard of care in dialysis - TradingView
Akebia Therapeutics, Inc. Announces Amendment to License Agreement for Drug Supply and Manufacturing Rights - MarketScreener
Akebia Therapeutics amends license agreement with Medice for Vafseo supply - Investing.com
Akebia Therapeutics amends license agreement with Medice for Vafseo supply By Investing.com - Investing.com South Africa
Akebia Therapeutics Inc says on Nov 12, co and Medice amend license agreement - MarketScreener
Analyzing Akebia Therapeutics Inc. with risk reward ratio charts2025 Trading Recap & Reliable Breakout Stock Forecasts - newser.com
Akebia Therapeutics Shares Extend Decline Amid Analyst Downgrades - Ad-hoc-news.de
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
FY2025 Earnings Forecast for AKBA Issued By Leerink Partnrs - MarketBeat
Akebia Therapeutics Inc. stock retracement – recovery analysisMarket Performance Recap & Growth Oriented Trading Recommendations - newser.com
Shareholders Alert: Investigation Into Akebia Therapeutics, Inc. (AKBA)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
How Akebia Therapeutics Inc. stock reacts to job market data2025 Price Targets & Community Consensus Picks - newser.com
Why Akebia Therapeutics Inc. (AX9) stock attracts wealthy investorsExit Point & AI Driven Price Predictions - newser.com
How rising interest rates impact Akebia Therapeutics Inc. stockQuarterly Profit Report & Accurate Technical Buy Alerts - newser.com
Akebia Therapeutics Inc Azioni (AKBA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.87%
2.78%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):